[1]汪晓琳,方 蕾,危 政.糖皮质激素、沙丁胺醇雾化吸入联合无创机械正压通气对COPD急性加重期患者血气指标及呼吸力学的影响[J].医学信息,2022,35(21):73-76.[doi:10.3969/j.issn.1006-1959.2022.21.016]
　WANG Xiao-lin,FANG Lei,WEI Zheng.Effect of Glucocorticoid and Salbutamol Atomization Inhalation Combined with Noninvasive Positive Pressure Ventilation on Blood Gas Index and Respiratory Mechanics in Patients with Acute Exacerbation of COPD[J].Journal of Medical Information,2022,35(21):73-76.[doi:10.3969/j.issn.1006-1959.2022.21.016]
点击复制

糖皮质激素、沙丁胺醇雾化吸入联合无创机械正压通气对COPD急性加重期患者血气指标及呼吸力学的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
73-76
栏目:
论著
出版日期:
2022-11-01

文章信息/Info

Title:
Effect of Glucocorticoid and Salbutamol Atomization Inhalation Combined with Noninvasive Positive Pressure Ventilation on Blood Gas Index and Respiratory Mechanics in Patients with Acute Exacerbation of COPD
文章编号:
1006-1959（2022）21-0073-04
作者:
汪晓琳; 方 蕾; 危 政
（玉山县中医院普内科1，ICU2，江西 玉山 334000）
Author(s):
WANG Xiao-lin; FANG Lei; WEI Zheng
(Department of General Internal Medicine1,ICU2,Yushan County Hospital of Traditional Chinese Medicine,Yushan 334000,Jiangxi,China)
关键词:
慢性阻塞性肺疾病; 沙丁胺醇; 糖皮质激素; 血气指标
Keywords:
Chronic obstructive pulmonary disease; Salbutamol; Glucocorticoids; Blood gas index
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.21.016
文献标志码:
A
摘要:
目的 评价给予急性加重期COPD患者沙丁醇胺、糖皮质激素联合无创正压通气治疗的效果及对患者呼吸力学指标和血气指标变化的影响。方法 选取2020年7月-2021年7月我院收治的COPD急性加重期患者68例，采用随机数字表法分为联合治疗组与对照组，每组34例。对照组给予无创机械通气加布地奈德雾化吸入治疗，联合治疗组在对照组的基础上给予沙丁胺醇雾化吸入治疗，比较两组血气指标（动脉血二氧化碳分压、动脉血氧分压、氧合指数）、呼吸力学指标[第1秒呼气的最大容积（FEV1）占用力肺活量（FVC）百分比、FVC、FEV1]、炎症因子[白介素-10（IL-10）、白介素-8（IL-8）、白介素-6（IL-6）]、生化指标（C-反应蛋白、白蛋白与球蛋白比值）及不良反应发生率。结果 联合治疗组氧合指数、动脉血氧分压高于对照组，动脉血二氧化碳分压低于对照组（P＜0.05）；联合治疗组FEV1/FVC%、FVC、FEV1高于对照组（P＜0.05）；联合治疗组IL-10、IL-8、IL-6低于对照组（P＜0.05）；联合治疗组C-反应蛋白低于对照组，白蛋白与球蛋白比值高于对照组（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 沙丁醇胺、糖皮质激素联合无创正压通气治疗急性加重期COPD患者效果良好，可促进患者呼吸力学指标、血气指标改善，降低炎性反应，且不增加不良反应，安全性较高。
Abstract:
Objective To evaluate the effect of salbutamol and glucocorticoid combined with non-invasive positive pressure ventilation in patients with acute exacerbation of COPD and its effect on the changes of respiratory mechanics and blood gas indexes.Methods A total of 68 patients with acute exacerbation of COPD admitted to our hospital from July 2020 to 2021 were selected and divided into combined treatment group and control group by random number table method, with 34 cases in each group. The control group was treated with noninvasive mechanical ventilation and budesonide atomization inhalation, and the combined treatment group was treated with salbutamol atomization inhalation on the basis of the control group. The blood gas indexes (arterial partial pressure of carbon dioxide, arterial partial pressure of oxygen, oxygenation index), respiratory mechanics indexes [percentage of maximum volume of first second expiratory (FEV1) in forced vital capacity (FVC), FVC, FEV1], inflammatory factors [interleukin-10 (IL-10), interleukin-8 (IL-8), interleukin-6(IL-6)], biochemical indexes (C-reactive protein, albumin to globulin ratio) and incidence of adverse reactions were compared between the two groups.Results The oxygenation index and arterial partial pressure of oxygen in the combined treatment group were higher than those in the control group, and the arterial partial pressure of carbon dioxide was lower than that in the control group (P<0.05). FEV1/FVC%, FVC and FEV1 in combined treatment group were higher than those in control group (P<0.05). The levels of IL-10, IL-8 and IL-6 in the combined treatment group were lower than those in the control group (P<0.05). The C-reactive protein in the combined treatment group was lower than that in the control group, and the ratio of albumin to globulin was higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Salbutamol amine, glucocorticoid combined with noninvasive positive pressure ventilation in the treatment of patients with acute exacerbation of COPD has good effect, which can promote the improvement of respiratory mechanics index, blood gas index, reduce the inflammatory reaction, and does not increase the adverse reactions, high safety.

参考文献/References:

[1]聂志.吸入用沙丁胺醇联合布地奈德对COPD急性加重期的作用[J].医学信息,2019,32(22):105-106.[2]Celli BR,Wedzicha JA.Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease[J].N Engl J Med,2019,381(13):1257-1266.[3]胡红旗,王立丽,史家欣,等.无创正压通气(ST模式)联合乙酰半胱氨酸对COPD合并Ⅱ型呼衰患者的疗效及预后的影响分析[J].中国急救复苏与灾害医学杂志,2020,15(9):1085-1087.[4]李晓俊,李亚,卞晴晴,等.中西医结合治疗对慢性阻塞性肺疾病痰热证急性加重-稳定期大鼠免疫因子的影响研究[J].中国全科医学,2022,25(2):197-205.[5]孙印,何士杰,韦海燕,等.布地奈德福莫特罗对慢性阻塞性肺疾病稳定期D组患者血清IL-17、IL-21、TLR4、mMRC分级及CAT评分的影响[J].临床内科杂志,2021,38(9):616-618.[6]邵宁,陶丽丽.沙丁胺醇联合布地奈德雾化吸入治疗慢性阻塞性肺疾病的临床效果[J].中国医药,2021,16(3):353-356.[7]刘琴.无创正压通气NIPPV两种通气模式治疗COPD合并Ⅱ型呼吸衰竭患者的疗效及安全性分析[J].河北医学,2019,25(4):668-671.[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.[9]中华医学会.临床诊疗指南/呼吸病学分册[M].北京:人民卫生出版社,2012:43.[10]Raad S,Smith C,Allen K.Nutrition Status and Chronic Obstructive Pulmonary Disease: Can We Move Beyond the Body Mass Index?[J].Nutr Clin Pract,2019,34(3):330-339.[11]Wang Z,Locantore N,Haldar K,et al.Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations:A Multicohort Longitudinal Analysis[J].Am J Respir Crit Care Med,2021,203(12):1488-1502.[12]孙田霞.噻托溴铵粉雾剂联合布地奈德福莫特罗粉吸入剂对COPD稳定期患者的疗效[J].河南医学研究,2020,29(15):2806-2807.[13]薛琳,龚启立,李晨鹏.噻托溴铵联合布地奈德、多索茶碱治疗老年慢性阻塞性肺疾病的效果[J].临床医学,2021,41(5):93-95.[14]江美芳,刘蔺,秦克.噻托溴铵联合无创呼吸机治疗COPD合并Ⅱ型呼吸衰竭疗效及对患者血气指标和炎症因子的影响[J].标记免疫分析与临床,2020,27(1):132-135,141.[15]薛丹,罗松,杨明,等.沙丁胺醇与不同种类、途径激素联合用药对AE-COPD的疗效及安全性分析[J].武警后勤学院学报(医学版),2019,28(7):58-61.[16]刘敬燕.沙丁胺醇联合中药穴位贴敷治疗慢性阻塞性肺病的疗效观察[J].湖南中医药大学学报,2019,39(3):376-380.[17]万东武,陈祥,詹茂芹,等.布地奈德、盐酸氨溴索和沙丁胺醇三联治疗COPD急性加重期患者的临床观察[J].临床和实验医学杂志,2020,28(22):2404-2407.[18]李菁.无创正压通气在急性加重期慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者中的应用效果及相关症状指标研究[J].中国药物与临床,2019,19(8):1316-1318.[19]李勇,何魏巍,王斐斐,等.无创正压通气联合沙丁胺醇及氨溴索治疗急性加重期慢性阻塞性肺疾病的临床效果观察[J].临床误诊误治,2020,33(6):28-32.[20]宋丁鼎,邱晓平,张彬,等.经鼻高流量氧疗和无创正压通气治疗老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效及安全性观察[J].贵州医药,2021,45(8):1250-1251.[21]任雨欣.煤工尘肺合并COPD患者长期规则使用舒利迭的效果[J].医学信息,2020,33(4):147-148.[22]李静,刘红梅,肖文香.糖皮质激素联合沙丁胺醇雾化吸入对慢阻肺急性加重期患者的疗效及肺功能,炎症因子的影响[J].海南医学,2021,32(16):2062-2065.[23]贾晓佳.莫西沙星溶液雾化吸入治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果及对机体相关指标的影响[J].中国医药,2019,14(7):984-987.[24]刘晓曼,胡秀娟,国莉莉,等.无创正压通气中SXX模式治疗对COPD合并Ⅱ型呼吸衰竭患者呼吸力学指标,肺功能及并发症的影响[J].解放军医药杂志,2021,33(6):59-62.[25]何淑霞,俞峭拔,孙小丽,等. 硫酸沙丁胺醇联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期患者的临床研究[J].中国临床药理学杂志,2020,36(12):1606-1609.[26]赵立群,万印利,张娟妮,等.噻托溴铵联合无创正压通气治疗对老年COPD合并呼吸衰竭患者生化指标的影响[J].海南医学,2020,31(1):34-37.[27]杨双嘉,邝敏,邓嘉宁,等.噻托溴铵联合无创正压通气对慢性阻塞性肺疾病合并Ⅱ型呼吸 衰竭患者症状评分,肺功能及血气分析指标的影响[J].广西医科大学学报,2020,37(1):61-67.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(21):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(21):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(21):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(21):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 1900-01-01